Plasmapheresis
K |
K |
||
| Zeile 5: | Zeile 5: | ||
{{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}} | {{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}} | ||
{{tp|p=32241301|t=2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 |pdf=|usr=}} | {{tp|p=32241301|t=2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 |pdf=|usr=}} | ||
| − | |||
{{tp|p=32391669|t=2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].|pdf=|usr=007}} | {{tp|p=32391669|t=2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].|pdf=|usr=007}} | ||
{{tp|p=32359878|t=2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19 |pdf=|usr=}} | {{tp|p=32359878|t=2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19 |pdf=|usr=}} | ||
| − | |||
{{tp|p=32258207|t=2020. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 |pdf=|usr=}} | {{tp|p=32258207|t=2020. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 |pdf=|usr=}} | ||
{{tp|p=32361195|t=ä. SARS-CoV-2 infection complicated by inflammatory syndrome Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?|pdf=|usr=}} | {{tp|p=32361195|t=ä. SARS-CoV-2 infection complicated by inflammatory syndrome Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?|pdf=|usr=}} | ||
| Zeile 22: | Zeile 20: | ||
{{tp|p=32585284|t=2020. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.|pdf=|usr=010}} | {{tp|p=32585284|t=2020. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.|pdf=|usr=010}} | ||
{{tp|p=32510799|t=2020. The Application Of Plasmapheresis For Covid-19 Patients.|pdf=|usr=007}} | {{tp|p=32510799|t=2020. The Application Of Plasmapheresis For Covid-19 Patients.|pdf=|usr=007}} | ||
| − | |||
{{tp|p=32552832|t=2020. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.|pdf=|usr=010}} | {{tp|p=32552832|t=2020. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.|pdf=|usr=010}} | ||
{{tp|p=32414417|t=2020. Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.|pdf=|usr=011}} | {{tp|p=32414417|t=2020. Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.|pdf=|usr=011}} | ||
{{tp|p=32534513|t=2020. COVID-19 Pandemic Hemoperfusion Therapy Versus Plasma Exchange Therapy in Intensive Care.|pdf=|usr=011}} | {{tp|p=32534513|t=2020. COVID-19 Pandemic Hemoperfusion Therapy Versus Plasma Exchange Therapy in Intensive Care.|pdf=|usr=011}} | ||
| − | |||
{{tp|p=32561113|t=2020. Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.|pdf=|usr=011}} | {{tp|p=32561113|t=2020. Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.|pdf=|usr=011}} | ||
{{tp|p=32380821|t=2020. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series.|pdf=|usr=011}} | {{tp|p=32380821|t=2020. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series.|pdf=|usr=011}} | ||
{{tp|p=32595974|t=2020. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure.|pdf=|usr=011}} | {{tp|p=32595974|t=2020. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure.|pdf=|usr=011}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
Aktuelle Version vom 18. Januar 2021, 21:04 Uhr
| PHA Serum products |
Plamapheresis, Immunoadsorption, IVIG, MARS, Cytosorb,
32247038 2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19
32241301 2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19
32391669 2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].
32359878 2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19
32258207 2020. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
32361195 ä. SARS-CoV-2 infection complicated by inflammatory syndrome Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?
32389697 ä. Plasmapheresis treatment in COVID-19?related autoimmune meningoencephalitis: Case series
32393681 2020. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.
32397847 2020. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.
32470601 2020. Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification.
32432784 2020. Editorial - High dose intravenous immunoglobulins as a therapeutic option for COVID-19 patients.
32283154 2020. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.
32426229 2020. Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia.
32454500 2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.
32505720 2020. Positive Outcome in a COVID-19 patient with Common Variable Immunodeficiency after IVIG.
32585284 2020. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.
32510799 2020. The Application Of Plasmapheresis For Covid-19 Patients.
32552832 2020. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.
32414417 2020. Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.
32534513 2020. COVID-19 Pandemic Hemoperfusion Therapy Versus Plasma Exchange Therapy in Intensive Care.
32561113 2020. Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.
32380821 2020. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series.
32595974 2020. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure.
